Literature DB >> 5026161

Ergot-induced inhibition of pituitary tumor growth in rats.

S K Quadri, K H Lu, J Meites.   

Abstract

Daily injections of ergocornine or ergonovine, for 3 weeks, into rats carrying a prolactin- and growth hormone-secreting pituitary tumor (MtW15) induced significant regression or inhibition of tumor growth, whereas ergocryptine had no significant effect. Ergocornine caused a decrease in cells and a disappearance or pycnosis of nuclei in the tumor tissue, and a reduced concentration of prolactin in blood.

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5026161     DOI： 10.1126/science.176.4033.417

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  14 in total

Review 1.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

Review 2.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

3.  The 'Alice in Wonderland' experience. Ergot alkaloid therapy for prolactin-secreting pituitary tumors.

Authors:  R C Williams; C Sherman; M T Buckman
Journal:  West J Med       Date:  1983-03

4.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

5.  Partial remission of hyperprolactinemic amenorrhea after bromocriptine-induced pregnancy.

Authors:  C Campagnoli; L Belforte; F Massara; C Peris; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

6.  Trends in the management of prolactinomas.

Authors: 
Journal:  Br Med J       Date:  1980-08-02

7.  Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology.

Authors:  M Nissim; B Ambrosi; V Bernasconi; G Giannattasio; M A Giovanelli; M Bassetti; U Vaccari; P Moriondo; A Spada; P Travaglini; G Faglia
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

8.  Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas.

Authors:  A M Landolt; H Minder; V Osterwalder; T A Landolt
Journal:  Experientia       Date:  1983-06-15

9.  Topical effect of bromocriptine on rat-transplanted human prolactinomas.

Authors:  B Açikgöz; T Ozgen; O E Ozcan; S Ruacan; T Erbengi; M Sumnu
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

10.  Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.

Authors:  G Verde; P G Chiodini; A Liuzzi; R Cozzi; F Favales; L Botalla; B Spelta; D Dalla Bonzana; E Rainer; R Horowski
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.